PGF.BE - Protagonist Therapeutics Inc
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 27.00 |
| Open | 27.00 |
| Bid | 26.60 x N/A |
| Ask | 27.60 x N/A |
| Day's Range | 26.00 - 27.00 |
| 52 Week Range | 6.55 - 27.60 |
| Volume | |
| Avg. Volume | 30 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
ACCESSWIREProtagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that a late-breaking abstract featuring blinded, randomized withdrawal data from the rusfertide (PTG-300) REVIVE Phase 2 study in polycythemia vera (PV) has been accepted for oral presentation at the European Hematology Association (EHA) 2023 Congress:
- ACCESSWIRE
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.
ZacksHow Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01%
The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BenzingaPromising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235). JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells. Also Read: Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study Although peptid
PR NewswireProtagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235), presented by Janssen and co-authored with Protagonist, as an oral presentation at the International Societies for Investigative Dermatology (ISID) 2023 meeting in Tokyo, Japan. The presentation, "First-in-class oral pept
- PR Newswire
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors at the JMP Securities Life Sciences Conference, an investor event taking place May 15-16, 2023 in New York, New York.
- PR Newswire
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that additional data from the REVIVE study of rusfertide in polycythemia vera will be presented in two posters at the annual Congress of the European Hematology Association (EHA), taking place June 8-11, 2023 in Frankfurt, Germany and virtually through June 15, 2023.
Investor's Business DailyProtagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
Shares of PTGX stock briefly broke out Friday after Protagonist said it plans to soon present new test results for its psoriasis drug.
- PR Newswire
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
Motley FoolWhy Shares of Protagonist Therapeutics Rose This Week
Shares of Protagonist Therapeutics (NASDAQ: PTGX) rose by 23.3% for the week, as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. Protagonist's stock jumped a bit because of increased interest in biotech stocks this week, particularly clinical-stage biotechs with promising therapies. Johnson & Johnson (NYSE: JNJ), through its subsidiary Janssen Biotech, already has a relationship with Protagonist and could see it as a potential buyout target.
Simply Wall St.Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Yet to Catch Up With Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 39.8x Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) is a...
- ACCESSWIRE
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share. Gross proceeds to Protagonist from the offering are expected to be $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the securities are being offered by Protagonist.
- ACCESSWIRE
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the securities to be sold in the offering are being offered by Protagonist.
ZacksStrength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength?
Nurix Therapeutics, Inc. (NRIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Simply Wall St.
Analysts Just Made A Major Revision To Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts
One thing we could say about the analysts on Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) - they aren't optimistic...
- Simply Wall St.
Protagonist Therapeutics (NASDAQ:PTGX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- ACCESSWIRE
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
BenzingaProtagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE of rusfertide for polycythemia vera, causing the bone marrow to make too many red blood cells. Subjects receiving rusfertide achieved highly statistically significant improvements versus placebo in the primary endpoint. More subjects receiving rusfertide during the blinded randomized withdrawal portion of the REVIVE study were responders compared wit
- ACCESSWIRE
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company"), today announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE, a study evaluating rusfertide, a subcutaneous injectable hepcidin mimetic, in patients with polycythemia vera (PV).
ZacksBiotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.
ZacksProtagonist (PTGX) Up on Positive Results From FRONTIER Study
Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.
ZacksProtagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BenzingaWhy Protagonist Therapeutics Shares Are Trading Higher Today
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from its collaboration with Janssen Biotech Inc, a part of Johnson & Johnson (NYSE: JNJ), in the FRONTIER 1 Phase 2b trial of oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis. Data from the 255-patient study showed that JNJ-2113 achieved the study's primary efficacy endpoint, with a statistically significant greater proportion of patients achieving PASI-75 (
- PR Newswire
Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company"), today announced positive topline results from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), in the FRONTIER 1 Phase 2b clinical trial evaluating the oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis.
ZacksProtagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.